Abstract Ethylene glycol poisoning is a common form of poisoning worldwide. The clinical course of ethylene glycol poisoning usually follows a three-stage progression, although these stages may overlap. A fourth stage of delayed neurological dysfunction consisting of cranial neuropathies has been suggested in several case reports. We describe a patient with unique findings of postural hypotension and gastroparesis following ethylene glycol toxicity with the additional uncommon features of albuminocytologic dissociation and increased intracranial pressure with papilledema. In addition, we provide a review of the literature on delayed neurological manifestations in ethylene glycol toxicity and further elucidate a description of a fourth stage of delayed neurological dysfunction following ethylene glycol poisoning.
Introduction
Ethylene glycol (EG) poisoning is a relatively common occurrence worldwide that can lead to significant morbidity and mortality [1] . Ethylene glycol (C 2 H 6 O 2 ) has a small molecular weight enabling it to increase the osmol gap early in toxic ingestions. However, it is EG's metabolism in the liver and the production of its toxic metabolites (glycoaldehyde, glycolic acid, glyoxalate, and oxalate) that are responsible for most of the clinical manifestations of poisoning.
The clinical course of ethylene glycol poisoning usually follows a three-step progression, the stages of which may overlap considerably [2, 3] :
Stage 1 (0.5 to 12 h post ingestion) consists of central nervous system (CNS) symptoms of inebriation, ataxia, seizure, coma and, with large enough doses, death. Irritation to the stomach may cause nausea and vomiting. Stage 2 (12 to 24 h post ingestion) is a result of accumulation of organic acids leading to cardiopulmonary syndrome that manifests as tachycardia, hypertension, tachypnea and pulmonary edema (cardiogenic and noncardiogenic). Stage 3 (24 to 72 h post ingestion) consists of renal failure resulting from osmotic damage and calcium oxalate deposition in the kidney. Metabolic acidosis can be found in all three stages of EG poisoning.
An additional stage four (days to weeks after ingestion) that manifests as delayed neurological deficits was originally suggested by Factor and Lava [4] in 1987 based on three case reports exhibiting cranial nerve deficits [5] [6] [7] following EG poisoning. The manifestation of this finding was likely due to better survival outcomes of severe EG poisoning which was often fatal in the first three phases before widespread use of hemodialysis. Since then, there have been other cases reporting findings of delayed cranial neuropathies [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Reports also describe cerebral edema [20, 21] , seizures [20, 22] , increased intracranial pressure with papilledema [16] and communicating hydrocephalus [11] , stroke [14, 23, 24] (one of which involved development of rapid onset Parkinson disease due to basal ganglia hemorrhagic infarction [24] ), diaphragmatic paralysis [13] , sensory radiculopathies [10, 12, 17, 25] , cerebrospinal fluid (CSF) findings of albuminocytologic dissociation [4, 9, 13, 25] as well as aseptic meningitis [8, 21, 26] . Some features of autonomic nervous system (ANS) dysfunction such as the bradycardia/tachycardia syndrome [14] and urinary retention with paralytic ileus [17] were reported; however, to our knowledge, postural hypotension and confirmed gastroparesis have not been previously described. Vomiting with delayed transit by barium follow through [12] has been reported; however, this is not a confirmatory test for gastroparesis and could represent a paralytic ileus. We report a case of EG poisoning that resulted in ANS dysfunction with postural hypotension and confirmed gastroparesis with the additional uncommon features of albuminocytologic dissociation (as seen in Guillain-Barre syndrome) and increased intracranial pressure with papilledema. We provide a review of late neurological manifestations of EG poisoning and further characterize a fourth stage of this illness consisting of delayed neurological dysfunction.
Case Report
An 18-year-old white male with a history of depression was brought to the emergency department in a state of confusion and agitation. His suicidal note stated that he had ingested half a gallon of ethylene glycol 10 h prior. On presentation he was tachycardic at 109 beats/min, his blood pressure was 178/100 mmHg and his respiratory rate was 22 breaths/min. He appeared combative and confused; the rest of the physical examination including his neurological examination was unremarkable. The patient was intubated for airway control and 100 g of activated charcoal was given via a nasogastric tube. Initial laboratory studies revealed a leukocytosis of 27,000 per cm 3 , blood urea nitrogen (BUN) of 11 mg/dl, serum creatinine concentration of 1.5 mg/dl, glucose of 145 mg/dl, serum sodium (Na) was 141 mmol/l, chloride (Cl) was 104 mmol/l and bicarbonate (HCO 3 ) of 6 mmol/l (anion gap was 31). An arterial blood gas was significant for evidence of metabolic acidosis with a serum pH of 7.05 and a PCO 2 of 35 mmHg, HCO 3 of 9.5 mmol/l, and a serum lactate of 9.7 mmol/l. His measured serum osmolality was 356 mOsm/kg, his calculated serum osmolarity was 294 mOsm/l yielding an osmol gap of 62 mOsm/kg. His serum alanine aminotransferase (ALT) was 72 units/dl, aspartate aminotransferase (AST) was 50 units/dl and a total bilirubin was 0.8 mg/dl. A serum toxicology screen for acetaminophen, salicylate, ethanol, and methanol was negative. A serum EG concentration was 1958 μg/ml (195 mg/dl). An electrocardiogram (EKG) was remarkable for sinus tachycardia of 109 beats/min and his chest radiograph was within normal limits. He was started on a continuous intravenous infusion of bicarbonate, was given appropriate intravenous doses of fomepizole (loading dose of 1.6 g followed by a maintenance dose of 1.1 g every 12 h for an additional two doses), and single doses of folate (100 mg), thiamine (100 mg) and pyridoxine (50 mg). The patient was emergently hemodialyzed for EG poisoning 5 h after initial presentation. Over the ensuing 16 h, the patient became anuric with a rising serum creatinine concentration. His metabolic acidosis progressively improved (pH 7.38, pCO 2 35 mmHg, HCO 3 23 mmol/l) and serum osmolality improved to 284 mOsm/kg. The patient was extubated 39 h after presentation to the ER. Hemodialysis was continued for his renal failure.
On day 13 of his hospitalization, the patient complained of a headache, photophobia, and blurring of vision with diplopia. Ophthalmological and neurological examinations revealed bilateral papilledema with normal visual acuity and a left sixth cranial nerve palsy. A lumbar puncture revealed a raised opening CSF pressure of 31 cm of H 2 O (normal <21 cm of H 2 O), a glucose of 61 mg/dl, a protein of 157 mg/dl and zero white blood cells (albuminocytologic dissociation). Magnetic resonance imaging (MRI) with gadolinium of the patient's head was within normal limits. The patient was started on acetazolamide to treat his elevated intracranial pressure with papilledema. One week later, the patient developed a left seventh cranial nerve palsy, and evidence of a sensory neuropathy in both feet (sharp pain and parasthesias on plantar surfaces). Strength, deep tendon reflexes, sensation to touch, temperature and vibration were all normal. Gabapentin was initiated to treat the neuropathy with improvement in symptoms noted.
In addition, the patient started to complain of dizziness on standing and was found to have postural hypotension (supine BP, 141/81 mmHg, standing BP, 108/66 mmHg) which did not resolve despite discontinuing his antihypertensive medications (labetolol and amlodipine). He also complained of persistent nausea and vomiting after meals. A gastric emptying study done 4 weeks after initiation of gastrointestinal symptoms showed mildly delayed gastric emptying of 111 min (normal, up to 90 min). His symptoms improved on oral metoclopromide of 10 mg every 6 h as needed.
Hemodialysis was discontinued 40 days after the initial presentation due to recovery of renal function and the patient was discharged home. The sixth and seventh cranial nerve palsies, papilledema, sensory radiculopathies and gastroparesis gradually resolved by 3 weeks after discharge; however, he continued to have asymptomatic orthostatic hypotension off all medications. M male, F female, EG ethylene glycol, HD hemodialysis, PD peritoneal dialysis, CN cranial nerve, SM sensorimotor, Rt right, Lt left, b/l bilateral, IV intravenous, CT computed tomography, MRI magnetic resonance imaging, CSF cerebrospinal fluid, ICP intracranial pressure, LP lumbar puncture, GP globus pallidus
Discussion
Our patient had evidence of ANS dysfunction in the form of radiologically confirmed gastroparesis and postural hypotension; this has not been previously reported as a complication of EG poisoning. None of his medications are known to cause postural hypotension. He received supplemental thiamine and pyridoxine to replenish the respective cofactors during his early hospitalization; thus ruling out their deficiencies as a cause of his neuropathy. Our patient also had the additional uncommon features of albuminocytologic dissociation and increased intracranial pressure with papilledema. This has been described previously in only a few cases as delayed neurotoxicity following EG intoxication. The originally reported delayed cranial nerves abnormal signs and symptoms occurring five to 20 days later [11] are unlikely to be explained by the immediate formation of toxic metabolites. Similarly, since tissue deposition (particularly in the kidneys, brain and lungs) of calcium oxalate crystals occurs within 3 to 6 h of ethylene glycol ingestion [11] , the direct deposition of calcium oxalate crystals in the tissues is also an unlikely explanation. Oxalate is a strong reducing agent and is toxic to endothelial cells [21] . Deposition of calcium oxalate crystals in cases of EG poisoning has been documented within small cerebral blood vessels walls and leptomeninges at post-mortem examinations [21, 26] . In 1979, Levinsky et al. [26] demonstrated deposition of calcium oxalate crystals in the walls of cerebral vessels with an infiltrate of neutrophils and mononuclear cells as well as proteinaceous fluid in the meninges and around parenchymal vessels. These changes can result in patchy focal necrosis with or without hemorrhage throughout the brain and chemical meningitis [26] . More recently, Froberg et al. [21] also found calcium oxalate crystals within vessel walls with prominent perivascular edema and collection of polymorphonuclear leukocytes adjacent to these vessels. Histologic evaluation of tissue sections of meninges showed a neutrophilic infiltrate [21] . Both autopsy investigations following EG poisoning have shown edema, hemorrhage and perivascular inflammation adjacent to small blood vessels in the brain suggesting exudative damage to the endothelial cells in these vessels causing nerve dysfunction [21, 26] . The time required to develop an inflammatory response to the endothelial injury may explain the delay in neurological sign and symptom manifestations [11, 21] (Table 1 [ ).
The ANS dysfunction, sensory radiculopathy and CSF finding of albuminocytologic dissociation observed in our patient likely resulted from vascular involvement and injury to the corresponding brain structures. His ANS dysfunction signs and symptoms may have resulted from involvement of the hypothalamus or vasomotor center [14] . The sensory radiculopathy and CSF findings may have resulted from meningial involvement covering the nerve roots.
The clinical outcome of patients reported to have developed these delayed neurological findings is variable (Table 1) . An overwhelming majority of patients who developed the fourth phase of EG toxicity were males (22 cases out of total 24). In those patients in whom treatment was reported, all underwent dialysis. The initial onset of delayed neurological symptoms varied from 3 to 20 days (confirming observation made by Lewis et al. [11] ) with an average of 9 days after ingestion of EG. A significant number of patients recovered their neurological function in 1 to 2 months after onset; in some patients the neurological deficits took longer to resolve and yet in others the neurological dysfunction persisted at 1 year of follow-up. The fastest recovery of neurological manifestations (17 days) was observed in a case treated with Dexamethasone [20] .
We hypothesize that the fourth phase of delayed neurological dysfunction is not limited to cranial nerve deficits but encompasses all features of neurological dysfunction and stems from the inflammatory response due to endothelial injury from calcium oxalate deposition.
In conclusion, physicians treating patients with EG poisoning should be aware of the potential for delayed neurotoxicity. Autonomic nervous system dysfunction manifesting as postural hypotension and gastroparesis can be associated with EG poisoning and should be recognized as part of the delayed neurological complications that can manifest after recovery from acute poisoning. More research is indicated to further elucidate the etiology of the neurological component of this illness.
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